Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
Pesqui. vet. bras ; 36(12): 1155-1159, Dec. 2016. tab
Article in English | LILACS, VETINDEX | ID: biblio-842035

ABSTRACT

In order to investigate the immune enhancement effects of Ophiopogon japonicus polysaccharide Ophiopogon japonicus (OJPS) on Newcastle disease (ND) live vaccine, chickens vaccinated against ND live vaccine was orally administered with the OJPS at high, medium and low concentrations respectively. In negative control group, chickens were given orally equal volume of physiological saline. On day 14, 21 and 28, the serum antibody titer, erythrocyte-C3b receptor rosette rate (E-C3bRR), erythrocyte-C3b immune complex rosette rate (E-ICRR) and peripheral lymphocyte proliferation were measured. The results showed that at most time points, the antibody titer, peripheral lymphocyte proliferation, E-C3bRR and elimination rate of immune complex of three OJPS administrating groups were significantly higher (P<0.05) than those in negative control group. It indicated that OJPS could significantly improve the immune efficacy of Newcastle disease live vaccine, Ophiopogon japonicus polysaccharide possessed synergistical immunoenhancement.(AU)


Subject(s)
Animals , Chickens/virology , Newcastle Disease/immunology , Ophiopogon/chemistry , Viral Vaccines/analysis , Adjuvants, Immunologic , Antibodies/blood , Erythrocytes/immunology , Lymphocytes/immunology
2.
Vet Immunol Immunopathol ; 158(1-2): 105-15, 2014 Mar 15.
Article in English | MEDLINE | ID: mdl-24368086

ABSTRACT

The onset and duration of immunity provided by a recombinant ND vaccine using HVT virus as vector (rHVT-ND) was followed up to 72 weeks of age in commercial layer chickens after single application or as part of two different vaccination regimes including conventional live and killed ND vaccines. Efficacy of the different vaccination programmes was checked, from 3 to 72 weeks of age, by serology as well as by challenges with a recent velogenic NDV isolate belonging to genotype VII. Assessment of protection was done based on the prevention of clinical signs and reduction of challenge virus shedding via the oro-nasal and cloacal routes. Single vaccination with the rHVT-ND vaccine at one day of age provided complete or almost complete (95-100%) clinical protection against NDV challenges from 4 weeks of age up to 72 weeks of age when the latest challenge was done. Shedding of challenge virus both by the oro-nasal and cloacal route was significantly reduced compared to the controls. Booster vaccination of rHVT-ND vaccinated birds with conventional ND vaccines significantly increased the level of anti-NDV serum antibodies and further reduced the oro-nasal excretion of challenge virus.


Subject(s)
Chickens , Herpesvirus 1, Meleagrid/immunology , Newcastle Disease/virology , Newcastle disease virus/immunology , Vaccines, Synthetic/immunology , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Enzyme-Linked Immunosorbent Assay/veterinary , Female , Newcastle Disease/immunology , Newcastle Disease/prevention & control , Random Allocation , Specific Pathogen-Free Organisms , Statistics, Nonparametric , Vaccination/standards , Vaccination/veterinary , Virus Shedding/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...